Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission.

Autor: Paul KK; Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas., Frey CG; Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas., Troung S; Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas., Paglicawan LVQ; Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas., Cunningham KA; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas., Preston Hill T; Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas., Bothwell LG; Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas., Golovko G; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas., Pillay Y; Department of Emergency Medicine, Michigan State University, East Lansing, Michigan., Jehle D; Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas.
Jazyk: angličtina
Zdroj: The western journal of emergency medicine [West J Emerg Med] 2024 Nov; Vol. 25 (6), pp. 869-874.
DOI: 10.5811/westjem.18569
Abstrakt: Introduction: As fentanyl has become more readily available, opioid-related morbidity and mortality in the United States has increased dramatically. Preliminary studies suggest that high-affinity, partial mu-opioid receptor agonists such as the combination product buprenorphine-naloxone may reduce mortality from overdose and promote remission. With the escalating prevalence of opioid use disorder (OUD), it is essential to evaluate the effectiveness of opioid agonists like buprenorphine-naloxone. This study examines mortality and remission rates for OUD patients prescribed buprenorphine-naloxone to determine the efficacy of this treatment toward these outcomes.
Methods: We carried out a retrospective analysis using the US Collaborative Network database in TriNetX, examining de-identified medical records from nearly 92 million patients across 56 healthcare organizations. The study spanned the years from January 1, 2017-May 13, 2022. Cohort 1 included OUD patients who began buprenorphine-naloxone treatment within one-year post-diagnosis, while Cohort 2, the control group, consisted of OUD patients who were not administered buprenorphine. The study measured mortality and remission rates within a year of the index event, incorporating propensity score matching for age, gender, and race/ethnicity.
Results: Prior to propensity matching, we identified a total of 221,967 patients with OUD. Following exclusions, 61,656 patients treated with buprenorphine-naloxone showed 34% fewer deaths within one year of diagnosis compared to 159,061 patients who did not receive buprenorphine (2.6% vs 4.0%; relative risk [RR] 0.661; 95% confidence interval [CI] 0.627-0.698; P  < 0.001). The remission rate was approximately 1.9 times higher in the buprenorphine-naloxone group compared to the control group (18.8% vs 10.1%; RR 1.862; 95% CI 1.812-1.914; P  < 0.001). After propensity matching, the effect on mortality decreased but remained statistically significant (2.6% vs 3.0%; RR 0.868; 95% CI 0.813-0.927; P  < 0.001) and the remission rate remained consistent (18.8% vs 10.4%; RR 1.812; 95% CI 1.750-1.876; P  < 0.001). Number needed to treat for benefit was 249 for death and 12 for remission.
Conclusion: Buprenorphine-naloxone was associated with significantly reduced mortality and increased remission rates for patients with opioid use disorder and should be used as a primary treatment. The recognition and implementation of treatment options like buprenorphine-naloxone is vital in alleviating the impact of OUD.
Competing Interests: Conflicts of Interest: By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. This research was supported by the Institute for Translational Sciences at The University of Texas Medical Branch, supported in part by a Clinical and Translational Science Award (UL1 TR001439) from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. There are no other conflicts of interest or sources of funding to declare.
Databáze: MEDLINE
Externí odkaz: